News & Comment

If biotech is to remain a wellspring of innovation, industry and academia need to do more to cultivate the next generation of entrepreneurial minds.

As sources of funding dwindle, could the health insurance sector do more to support biotech innovation and help itself at the same time?

The gobs of data produced by next-generation sequencing are a key problem limiting wider adoption.

Researchers and their institutions need to dispel a myth about 'independent' research before the media does it for them.

Disease-orientated consumer online communities radically change the way in which individuals monitor their health, but they could also create new ways of testing treatments and speed patient recruitment into clinical trials.

Does a role-playing game reveal any new insights into the factors holding back the UK biotech sector?

Pushing biotech as the 'solution' to the world's problems is doing more harm than good.

With follow-on biologics essentially dead in the water in the US, the decision of the world's largest generics manufacturer to invest in a platform for enhancing protein pharmacokinetics could pay dividends.

Moves to clamp down on companies offering direct-to-consumer genetic tests are out of step with personal genomics and its potential to empower individuals' role in their own healthcare.

The heparin scare highlights the need not only for more effective systems of adverse event reporting and product tracking, but also for drug makers to tighten scrutiny of their suppliers.

Based on one company's past poor publishing practices, a top-tier medical journal misguidedly stigmatizes any paper from industry.

Amgen's retrospective sortie into personalized Vectibix treatment poses some difficult questions for regulators concerning the oversight of companion diagnostics.

The first blog from a biotech company goes live.

Global health initiatives should place greater emphasis on mechanisms for encouraging small and medium-sized biotech enterprises to participate in the fight against neglected diseases.

To restore its scientific credibility, the International Assessment of Agricultural Science and Technology for Development (IAASTD) should rethink its vision for biotech.

Last year's R&D output by the drug industry was the worst in a generation. But amid the dismal numbers, there is evidence that more innovative medicines are reaching patients.

Pressure is mounting on the US Food and Drug Administration (FDA) to explain its decision to ignore an advisory committee's positive recommendation for the cancer vaccine Provenge.